- Home
- ANVS vs ACRS Comparison
ANVS vs ACRS Comparison
Compare ANVS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- ACRS
- Stock Information
- Founded
- ANVS 2008
- ACRS 2012
- Country
- ANVS United States
- ACRS United States
- Employees
- ANVS N/A
- ACRS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- ACRS Health Care
- Exchange
- ANVS Nasdaq
- ACRS Nasdaq
- Market Cap
- ANVS 110.4M
- ACRS 132.0M
- IPO Year
- ANVS 2020
- ACRS 2015
- Fundamental
- Price
- ANVS $6.85
- ACRS $2.05
- Analyst Decision
- ANVS Strong Buy
- ACRS Hold
- Analyst Count
- ANVS 6
- ACRS 4
- Target Price
- ANVS $29.67
- ACRS $1.00
- AVG Volume (30 Days)
- ANVS 261.0K
- ACRS 1.3M
- Earning Date
- ANVS 11-08-2024
- ACRS 11-06-2024
- Dividend Yield
- ANVS N/A
- ACRS N/A
- EPS Growth
- ANVS N/A
- ACRS N/A
- EPS
- ANVS N/A
- ACRS N/A
- Revenue
- ANVS N/A
- ACRS $27,079,000.00
- Revenue This Year
- ANVS N/A
- ACRS N/A
- Revenue Next Year
- ANVS N/A
- ACRS N/A
- P/E Ratio
- ANVS N/A
- ACRS N/A
- Revenue Growth
- ANVS N/A
- ACRS 26.35
- 52 Week Low
- ANVS $4.53
- ACRS $0.77
- 52 Week High
- ANVS $22.49
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- ANVS 30.84
- ACRS 55.69
- Support Level
- ANVS $7.30
- ACRS $2.09
- Resistance Level
- ANVS $8.93
- ACRS $2.72
- Average True Range (ATR)
- ANVS 0.56
- ACRS 0.26
- MACD
- ANVS -0.26
- ACRS -0.01
- Stochastic Oscillator
- ANVS 4.89
- ACRS 40.71
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.